The dna and gene chip market size has grown rapidly in recent years. It will grow from $9.2 billion in 2025 to $10.45 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to expansion of genomic research activities, increasing adoption of molecular diagnostics, growth of cancer research programs, rising availability of advanced microarray platforms, expansion of academic genomics funding.
The dna and gene chip market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising investments in genomics-based drug discovery, expansion of population-scale genetic screening, growing adoption of ai-driven genomic analytics, increasing use of gene chips in agrigenomics. Major trends in the forecast period include increasing adoption of high-density gene expression arrays, rising use of single-cell analysis chips, growing demand for precision oncology diagnostics, expansion of snp and whole genome analysis chips, enhanced focus on high-throughput genomic screening.
The growing emphasis on early cancer detection is playing a major role in driving the expansion of the DNA and gene chip market. Cancer refers to a wide range of diseases that can originate in almost any organ or tissue when abnormal cells grow uncontrollably, breach normal cellular boundaries, invade surrounding tissues, and spread to other parts of the body. The demand for early detection is increasing as awareness rises about the advantages of identifying cancer at an early stage, encouraging individuals to undergo timely screening that can significantly improve treatment effectiveness and survival rates. DNA and gene chips are widely used to analyze gene expression profiles, assess genetic and epigenetic alterations, and evaluate genomic regulatory elements associated with cancer-related transcription factors in malignant cells. For example, in May 2025, a report published by the National Cancer Institute indicated that the United States is expected to record around 2,041,910 new cancer cases and approximately 618,120 cancer-related deaths in 2025. Similarly, in 2022, data from the American Cancer Society projected nearly 1.9 million newly diagnosed cancer cases and 609,360 deaths in the United States. Consequently, the increasing focus on early cancer detection is supporting the growth of the DNA and gene chip market.
Key players in the DNA and gene chip market are developing innovative genotyping chips, such as the Axiom YNS_Mol1, to advance the food industry and promote insect consumption. The Axiom YNS_Mol1 is a genotyping chip specifically designed for insect breeding, particularly for the Tenebrio Molitor mealworm. For instance, in June 2023, Ÿnsect, a France-based company specializing in insect production, introduced the world's first genotyping chip for insect breeding, the Axiom YNS_Mol1. Developed in collaboration with Thermo Fisher Scientific, this pioneering chip aims to transform insect breeding for sustainable food and pet food production. It analyzes genetic traits to enhance genomic diversity and improve characteristics such as growth, reproduction, and disease resistance in Tenebrio Molitor mealworms. This innovative initiative is part of Ÿnsect's ŸnFABRE project, contributing to the advancement of entomoculture and sustainable solutions in addressing environmental challenges.
In December 2024, Hendrix Genetics, a Netherlands-based animal breeding technology company, entered into a partnership with LABOGENA DNA to obtain exclusive access to high-throughput genotyping services for its multi-species breeding programs. Through this collaboration, Hendrix Genetics seeks to strengthen and accelerate its genotyping capabilities, enabling improved genetic gains across multiple species by leveraging LABOGENA DNA’s advanced genotyping infrastructure. LABOGENA DNA, a France-based industrial genotyping and sequencing company, specializes in high-throughput single nucleotide polymorphism (SNP) chip genotyping, targeted sequencing, DNA extraction, custom SNP matrix development, and research and development consulting services, all delivered from its International Organization for Standardization (ISO) 17025-accredited laboratory located near Paris.
Major companies operating in the dna and gene chip market are Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., CapitalBio Corporation, Microarrays Inc., Applied Microarrays Inc., Biometrix Technology Inc., Oxford Gene Technology IP Limited, Bioneer Corporation, QIAGEN N.V., Bio-Rad Laboratories Inc., BioChain Institute Inc., Fluidigm Corporation, LC Sciences, Macrogen Inc., Greiner Bio-One International GmbH, F. Hoffmann-La Roche Ltd, GE Healthcare, Hitachi High-Technologies Corporation.
North America was the largest region in the DNA and gene chip market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna and gene chip market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna and gene chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the dna and gene chip market by increasing costs of imported microarray substrates, reagents, scanners, and semiconductor-based fabrication equipment used in chip production. Research institutions and biotechnology companies in North America and Europe are most affected due to dependence on imported precision components, while Asia-Pacific faces higher costs for export-oriented chip manufacturing. These tariffs are increasing procurement expenses and slowing laboratory upgrades. However, they are also encouraging localized manufacturing, domestic reagent production, and regional expansion of genomics fabrication facilities.
The dna and gene chip market research report is one of a series of new reports that provides dna and gene chip market statistics, including dna and gene chip industry global market size, regional shares, competitors with a dna and gene chip market share, detailed dna and gene chip market segments, market trends and opportunities, and any further data you may need to thrive in the dna and gene chip industry. This dna and gene chip market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A DNA and gene chip is a microchip featuring microscopic DNA probes attached to a solid surface, capable of identifying DNA from test samples and constituting one half of the DNA double helix. When the test sample of DNA carries a mutation, the DNA fails to bind properly to the sequence on the chip. This technology is employed to measure the expression levels of genes or determine whether a person's DNA exhibits mutations, variations in DNA that can lead to diseases.
The main types of DNA and gene chips include oligonucleotide DNA (O-DNA), complementary DNA (C-DNA), and other variations. Oligonucleotide DNA comprises short single- or double-stranded DNA or RNA fragments with three to twenty nucleotides. Products associated with this technology include consumables and instruments, with applications ranging from cancer diagnostics, gene expression, proteomics, genomics, drug discovery, to agrigenomics. End-user industries involved encompass academic and government research institutes, biotechnology and pharmaceutical companies, hospitals and diagnostics centers, among others.
The DNA and gene chip market consists of sales of instrumentation and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The dna and gene chip market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising investments in genomics-based drug discovery, expansion of population-scale genetic screening, growing adoption of ai-driven genomic analytics, increasing use of gene chips in agrigenomics. Major trends in the forecast period include increasing adoption of high-density gene expression arrays, rising use of single-cell analysis chips, growing demand for precision oncology diagnostics, expansion of snp and whole genome analysis chips, enhanced focus on high-throughput genomic screening.
The growing emphasis on early cancer detection is playing a major role in driving the expansion of the DNA and gene chip market. Cancer refers to a wide range of diseases that can originate in almost any organ or tissue when abnormal cells grow uncontrollably, breach normal cellular boundaries, invade surrounding tissues, and spread to other parts of the body. The demand for early detection is increasing as awareness rises about the advantages of identifying cancer at an early stage, encouraging individuals to undergo timely screening that can significantly improve treatment effectiveness and survival rates. DNA and gene chips are widely used to analyze gene expression profiles, assess genetic and epigenetic alterations, and evaluate genomic regulatory elements associated with cancer-related transcription factors in malignant cells. For example, in May 2025, a report published by the National Cancer Institute indicated that the United States is expected to record around 2,041,910 new cancer cases and approximately 618,120 cancer-related deaths in 2025. Similarly, in 2022, data from the American Cancer Society projected nearly 1.9 million newly diagnosed cancer cases and 609,360 deaths in the United States. Consequently, the increasing focus on early cancer detection is supporting the growth of the DNA and gene chip market.
Key players in the DNA and gene chip market are developing innovative genotyping chips, such as the Axiom YNS_Mol1, to advance the food industry and promote insect consumption. The Axiom YNS_Mol1 is a genotyping chip specifically designed for insect breeding, particularly for the Tenebrio Molitor mealworm. For instance, in June 2023, Ÿnsect, a France-based company specializing in insect production, introduced the world's first genotyping chip for insect breeding, the Axiom YNS_Mol1. Developed in collaboration with Thermo Fisher Scientific, this pioneering chip aims to transform insect breeding for sustainable food and pet food production. It analyzes genetic traits to enhance genomic diversity and improve characteristics such as growth, reproduction, and disease resistance in Tenebrio Molitor mealworms. This innovative initiative is part of Ÿnsect's ŸnFABRE project, contributing to the advancement of entomoculture and sustainable solutions in addressing environmental challenges.
In December 2024, Hendrix Genetics, a Netherlands-based animal breeding technology company, entered into a partnership with LABOGENA DNA to obtain exclusive access to high-throughput genotyping services for its multi-species breeding programs. Through this collaboration, Hendrix Genetics seeks to strengthen and accelerate its genotyping capabilities, enabling improved genetic gains across multiple species by leveraging LABOGENA DNA’s advanced genotyping infrastructure. LABOGENA DNA, a France-based industrial genotyping and sequencing company, specializes in high-throughput single nucleotide polymorphism (SNP) chip genotyping, targeted sequencing, DNA extraction, custom SNP matrix development, and research and development consulting services, all delivered from its International Organization for Standardization (ISO) 17025-accredited laboratory located near Paris.
Major companies operating in the dna and gene chip market are Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., CapitalBio Corporation, Microarrays Inc., Applied Microarrays Inc., Biometrix Technology Inc., Oxford Gene Technology IP Limited, Bioneer Corporation, QIAGEN N.V., Bio-Rad Laboratories Inc., BioChain Institute Inc., Fluidigm Corporation, LC Sciences, Macrogen Inc., Greiner Bio-One International GmbH, F. Hoffmann-La Roche Ltd, GE Healthcare, Hitachi High-Technologies Corporation.
North America was the largest region in the DNA and gene chip market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna and gene chip market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna and gene chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the dna and gene chip market by increasing costs of imported microarray substrates, reagents, scanners, and semiconductor-based fabrication equipment used in chip production. Research institutions and biotechnology companies in North America and Europe are most affected due to dependence on imported precision components, while Asia-Pacific faces higher costs for export-oriented chip manufacturing. These tariffs are increasing procurement expenses and slowing laboratory upgrades. However, they are also encouraging localized manufacturing, domestic reagent production, and regional expansion of genomics fabrication facilities.
The dna and gene chip market research report is one of a series of new reports that provides dna and gene chip market statistics, including dna and gene chip industry global market size, regional shares, competitors with a dna and gene chip market share, detailed dna and gene chip market segments, market trends and opportunities, and any further data you may need to thrive in the dna and gene chip industry. This dna and gene chip market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A DNA and gene chip is a microchip featuring microscopic DNA probes attached to a solid surface, capable of identifying DNA from test samples and constituting one half of the DNA double helix. When the test sample of DNA carries a mutation, the DNA fails to bind properly to the sequence on the chip. This technology is employed to measure the expression levels of genes or determine whether a person's DNA exhibits mutations, variations in DNA that can lead to diseases.
The main types of DNA and gene chips include oligonucleotide DNA (O-DNA), complementary DNA (C-DNA), and other variations. Oligonucleotide DNA comprises short single- or double-stranded DNA or RNA fragments with three to twenty nucleotides. Products associated with this technology include consumables and instruments, with applications ranging from cancer diagnostics, gene expression, proteomics, genomics, drug discovery, to agrigenomics. End-user industries involved encompass academic and government research institutes, biotechnology and pharmaceutical companies, hospitals and diagnostics centers, among others.
The DNA and gene chip market consists of sales of instrumentation and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. DNA and Gene Chip Market Characteristics
3. DNA and Gene Chip Market Supply Chain Analysis
4. Global DNA and Gene Chip Market Trends and Strategies
5. DNA and Gene Chip Market Analysis of End Use Industries
7. Global DNA and Gene Chip Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global DNA and Gene Chip Total Addressable Market (TAM) Analysis for the Market
9. DNA and Gene Chip Market Segmentation
10. DNA and Gene Chip Market Regional and Country Analysis
11. Asia-Pacific DNA and Gene Chip Market
12. China DNA and Gene Chip Market
13. India DNA and Gene Chip Market
14. Japan DNA and Gene Chip Market
15. Australia DNA and Gene Chip Market
16. Indonesia DNA and Gene Chip Market
17. South Korea DNA and Gene Chip Market
18. Taiwan DNA and Gene Chip Market
19. South East Asia DNA and Gene Chip Market
20. Western Europe DNA and Gene Chip Market
21. UK DNA and Gene Chip Market
22. Germany DNA and Gene Chip Market
23. France DNA and Gene Chip Market
24. Italy DNA and Gene Chip Market
25. Spain DNA and Gene Chip Market
26. Eastern Europe DNA and Gene Chip Market
27. Russia DNA and Gene Chip Market
28. North America DNA and Gene Chip Market
29. USA DNA and Gene Chip Market
30. Canada DNA and Gene Chip Market
31. South America DNA and Gene Chip Market
32. Brazil DNA and Gene Chip Market
33. Middle East DNA and Gene Chip Market
34. Africa DNA and Gene Chip Market
36. DNA and Gene Chip Market Competitive Landscape and Company Profiles
37. DNA and Gene Chip Market Other Major and Innovative Companies
40. DNA and Gene Chip Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
DNA And Gene Chip Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses dna and gene chip market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dna and gene chip? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dna and gene chip market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Oligonucleotide DNA (o-DNA); Complementary DNA (c-DNA)2) By Application: Cancer Diagnostics; Gene Expression; Genomics; Drug Discovery; Agrigenomics
3) By End User: Academic And Government Research Institutes; Biotechnology And Pharmaceutical Companies; Hospitals And Diagnostics Centers; Other End Users
Subsegments:
1) By Oligonucleotide DNA (o-DNA): Custom Oligonucleotide Chips; Commercial Oligonucleotide Arrays2) By Complementary DNA (c-DNA): cDNA Microarrays; cDNA Expression Arrays
Companies Mentioned: Illumina Inc.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; PerkinElmer Inc.; CapitalBio Corporation; Microarrays Inc.; Applied Microarrays Inc.; Biometrix Technology Inc.; Oxford Gene Technology IP Limited; Bioneer Corporation; QIAGEN N.V.; Bio-Rad Laboratories Inc.; BioChain Institute Inc.; Fluidigm Corporation; LC Sciences; Macrogen Inc.; Greiner Bio-One International GmbH; F. Hoffmann-La Roche Ltd; GE Healthcare; Hitachi High-Technologies Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this DNA and Gene Chip market report include:- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- PerkinElmer Inc.
- CapitalBio Corporation
- Microarrays Inc.
- Applied Microarrays Inc.
- Biometrix Technology Inc.
- Oxford Gene Technology IP Limited
- Bioneer Corporation
- QIAGEN N.V.
- Bio-Rad Laboratories Inc.
- BioChain Institute Inc.
- Fluidigm Corporation
- LC Sciences
- Macrogen Inc.
- Greiner Bio-One International GmbH
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Hitachi High-Technologies Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.45 Billion |
| Forecasted Market Value ( USD | $ 16.99 Billion |
| Compound Annual Growth Rate | 12.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
